Chromosome alignment in HeLa cells
Cell-based study · HeLa S3 [1]
HeLa S3 cells were treated with 5 µM PQ401 or solvent control (DMSO) for 24 h. During the last 20 h of inhibitor treatment, cells were treated with 6 µM RO-3306 in the presence of inhibitors. M-phase cells: only 22% of solvent (dimethyl sulfoxide) control cells did not align their chromosomes and were classified as P/PM; more than 45% of cells did not align their chromosomes upon treatment with 5 µM PQ401.
| Endpoint | Reported result | Reference |
|---|---|---|
| M-phase cells: prophase/prometaphse (P/PM) | prophase/prometaphase cells 5 µM PQ401: more than 45% of M-phase cells | [1] |
Literature-Reported Treatment Conditions
- Treatment concentration
- 5 µM
- Exposure duration
- for 24 h; During the last 20 h of inhibitor treatment; After 50 min, cells were fixed
- Method
- in the presence of inhibitors
- Vehicle
- DMSO
- Co-treatment
- Other interventions in this design: RO-3306 6 µM. Compound effect isolated by the comparison: solvent control (DMSO).
Methods and source locations
Compound reported in the paper: PQ 401
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
2. Results > 2.3. Delay in M-Phase Progression by IGF1R Inhibitors (S54); 4. Materials and Methods > 4.2. Chemicals (S108); 4. Materials and Methods > 4.4. Antibodies (S112); 4. Materials and Methods > 4.5. Immunofluorescence Microscopy (S117); Figure 5 legend (S217, S218, S220, S221)
M-phase cells: prophase/prometaphse (P/PM): M-phase cells: prophase/prometaphse (P/PM); comparator: solvent control (DMSO) — 2. Results > 2.3. Delay in M-Phase Progression by IGF1R Inhibitors (S54); Figure 5 legend (S221)